Skyrizi wiki?

What is Skyrizi and How Does It Work?

Skyrizi is a medication used to treat certain autoimmune conditions, including psoriasis and Crohn's disease. It is administered via injection under the skin and works by blocking the activity of a protein called IL-23, which plays a key role in the development of these conditions.

How Long Has Skyrizi Been Available?

Skyrizi was approved by the FDA in September 2018 for the treatment of moderate to severe plaque psoriasis in adults. It was later approved for the treatment of active Crohn's disease in December 2020.

Why Are Companies Challenging the Patent for Skyrizi?

The patent for Skyrizi is set to expire in 2034, which is still several years away. However, as the patent expires, other companies may be able to develop biosimilars, or generic versions of the drug, which could compete with Skyrizi in the market.

How Does Skyrizi Compare to Other Psoriasis Treatments?

Studies have shown that Skyrizi is effective in treating moderate to severe plaque psoriasis, with a response rate of over 80% in clinical trials. It is generally well-tolerated, with the most common side effects being injection site reactions, fatigue, and diarrhea.

What Are the Side Effects of Skyrizi?

Common side effects of Skyrizi include injection site reactions, fatigue, diarrhea, and headache. Rare but serious side effects include serious infections, allergic reactions, and an increased risk of lymphoma. Patients taking Skyrizi should be closely monitored for these side effects.

Can Biosimilars Enter the Market Before the Patent Expiration Date?

Under the Biologics Price Competition and Innovation Act of 2009, biosimilars can enter the market before the patent expiration date if they demonstrate biosimilarity to the reference product. However, as of now, no biosimilars have entered the market for Skyrizi.

Sources:

[1] FDA approves ustekinumab injection for moderate to severe plaque psoriasis (https://www.fda.gov/news-events/press-announcements/fda-approves-ustekinumab-injection-moderate-severe-plaque-psoriasis)
[2] FDA approves ustekinumab injection for active Crohn’s disease (https://www.fda.gov/news-events/press-announcements/fda-approves-ustekinumab-injection-active-crohns-disease)
[3] Skyrizi (USTEKINUMAB) Package Insert (https://drugpatentwatch.com/patent/US-10684441/)
[4] Biosimilar Development for Complex Biologics (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436548/)
[5] Ustekinumab for the Treatment of Psoriasis (https://pubmed.ncbi.nlm.nih.gov/30814367/)